Yet, preclinical studies indicate that AT2 receptor agonists are not suitable as a monotherapy for cardiovascular disease and that at best, AT2 receptor agonists may be beneficial in combination with existing RAS inhibitors (Danyel et al., 2013). The gene discussed is AGTR2; the disease is cardiovascular disorder.